Genetic, Immunologic, and Immunohistochemical Analysis of the Programmed Death 1/Programmed Death Ligand 1 Pathway in Human Systemic Lupus Erythematosus

被引:105
作者
Bertsias, George K.
Nakou, Magda
Choulaki, Christlanna
Raptopoulou, Amalia
Papadimitraki, Eva
Goulielmos, George
Kritikos, Herakles
Sidiropoulos, Prodromos
Tzardi, Maria
Kardassis, Dimitris [1 ]
Mamalaki, Clio [2 ]
Boumpas, Dimitrios T.
机构
[1] Univ Crete, Sch Med, Lab Autoimmun & Inflammat Rheumatol Clin Immunol, Iraklion 71500, Crete, Greece
[2] Fdn Res & Technol Hellas, Iraklion, Crete, Greece
来源
ARTHRITIS AND RHEUMATISM | 2009年 / 60卷 / 01期
关键词
T-CELL TOLERANCE; MIXED LYMPHOCYTE-REACTION; RUNX1; BINDING-SITE; RHEUMATOID-ARTHRITIS; REGULATING AUTOIMMUNITY; DENDRITIC CELLS; PD-1; DISEASE; PDCD1; POLYMORPHISM;
D O I
10.1002/art.24227
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. A putative regulatory intronic polymorphism (PD1.3) in the programmed death 1 (PD-1) gene, a negative regulator of T cells involved in peripheral tolerance, is associated with increased risk for systemic lupus erythematosus (SLE). We undertook this study to determine the expression and function of PD-1 in SLE patients. Methods. We genotyped 289 SLE patients and 256 matched healthy controls for PD1.3 by polymerase chain reaction-restriction fragment length polymorphism analysis. Expression of PD-1 and its ligand, PDL-1, was determined in peripheral blood lymphocytes and in renal biopsy samples by now cytometry and immunohistochemistry. A crosslinker of PD-1 was used to assess its effects on anti-CD3/anti-CD28-induced T cell proliferation and cytokine production. Results. SLE patients had an increased frequency of the PD1.3 polymorphism (30.1%, versus 18.4% in controls; P = 0.006), with the risk A allele conferring decreased transcriptional activity in transfected Jurkat cells. Patients homozygous for PD1.3-but not patients heterozygous for PD1.3-had reduced basal and induced PD-1 expression on activated CD4+ T cells. In autologous mixed lymphocyte reactions (AMLRs), SLE patients had defective PD-1 induction on activated CD4+ cells; abnormalities were more pronounced among homozygotes. PD-1 was detected within the glomeruli and renal tubules of lupus nephritis patients, while PDL-1 was expressed by the renal tubules of both patients and controls. PD-1 crosslinking suppressed proliferation and cytokine production in both normal and lupus T cells; addition of serum from patients with active SLE significantly ameliorated this effect on proliferation. Conclusion, SLE patients display aberrant expression and function of PD-1 attributed to both direct and indirect effects. The expression of PD-1/PDL-1 in renal tissue and during AMLRs suggests an important role in regulating peripheral T cell tolerance.
引用
收藏
页码:207 / 218
页数:12
相关论文
共 40 条
  • [21] Cutting edge:: Programed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens
    Martin-Orozco, Natalia
    Wang, Yi-Hong
    Yagita, Hideo
    Dong, Chen
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 177 (12) : 8291 - 8295
  • [22] Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9
    Means, TK
    Latz, E
    Hayashi, F
    Murali, MR
    Golenbock, DT
    Luster, AD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) : 407 - 417
  • [23] Ethnic differences in allele frequency of autoimmune-disease-associated SNPs
    Mori, M
    Yamada, R
    Kobayashi, K
    Kawaida, R
    Yamamoto, K
    [J]. JOURNAL OF HUMAN GENETICS, 2005, 50 (05) : 264 - 266
  • [24] T-cell tolerance or function is determined by combinatorial costimulatory signals
    Nurieva, Roza
    Thomas, Sunil
    Nguyen, Thang
    Martin-Orozco, Natalia
    Wang, Ying
    Kaja, Murali-Krishna
    Yu, Xue-Zhong
    Dong, Chen
    [J]. EMBO JOURNAL, 2006, 25 (11) : 2623 - 2633
  • [25] The PD-1-PD-L pathway in immunological tolerance
    Okazaki, T
    Honjo, T
    [J]. TRENDS IN IMMUNOLOGY, 2006, 27 (04) : 195 - 201
  • [26] CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
    Parry, RV
    Chemnitz, JM
    Frauwirth, KA
    Lanfranco, AR
    Braunstein, I
    Kobayashi, SV
    Linsley, PS
    Thompson, CB
    Riley, JL
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (21) : 9543 - 9553
  • [27] The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis
    Prokunina, L
    Gunnarsson, I
    Sturfelt, G
    Truedsson, L
    Seligman, VA
    Olson, JL
    Seldin, MF
    Criswell, LA
    Alarcón-Riquelme, ME
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (01): : 327 - 328
  • [28] A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans
    Prokunina, L
    Castillejo-López, C
    Öberg, F
    Gunnarsson, I
    Berg, L
    Magnusson, V
    Brookes, AJ
    Tentler, D
    Kristjansdóttir, H
    Gröndal, G
    Bolstad, AI
    Svenungsson, E
    Lundberg, I
    Sturfelt, G
    Jönssen, A
    Truedsson, L
    Lima, G
    Alcocer-Varela, J
    Jonsson, R
    Gyllensten, UB
    Harley, JB
    Alarcón-Segovia, D
    Steinsson, K
    Alarcón-Riquelme, ME
    [J]. NATURE GENETICS, 2002, 32 (04) : 666 - 669
  • [29] Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcγRII dependent mechanism:: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE
    Rönnelid, J
    Tejde, A
    Mathsson, L
    Nilsson-Ekdahl, K
    Nilsson, B
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (01) : 37 - 42
  • [30] PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion
    Saunders, PA
    Hendrycks, VR
    Lidinsky, WA
    Woods, ML
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (12) : 3561 - 3569